Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed Glioblastoma

Next Previous
Trial Profile

An Open-label Dose Escalation Study to Estimate MTD, Identify DLTs and Study Pharmacokinetics Following a Single Dose of Intracranially Administered Temozolomide-based SI-053 as an add-on to the Current Standard of Care, in Adult Patients With Newly Diagnosed Glioblastoma

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Acronyms TARGLIO
  • Sponsors Double Bond Pharmaceutical

Most Recent Events

  • 10 Mar 2025 According to A Double Bond Pharmaceutical media release, candidate SI-053 received Orphan Drug Designation from the European Medicines Agency (EMA) in 2016 and has recently obtained Competent Authority and Ethics Committee approvals to initiate a Phase 1 clinical trial in two Western European countries.
  • 04 Jul 2023 Planned End Date changed from 1 Aug 2025 to 1 Dec 2025.
  • 04 Jul 2023 Planned primary completion date changed from 1 Jun 2025 to 1 Jul 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top